Literature DB >> 31821814

Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure.

Francesco Giorgino1, Irene Caruso2, Julia Moellmann3, Michael Lehrke4.   

Abstract

SGLT-2 inhibitors and most GLP-1 receptor agonists demonstrated cardiovascular superiority and reduction of cardiovascular and overall mortality. These results stand as a turning point in the management of diabetes, shifting the focus from controlling glucose levels to mastering the extra-glycemic effects of these new drugs. This narrative review will discuss recent CVOT with focus on SGLT-2 inhibitors and GLP-1 receptor agonists to distinguish relevant patients' characteristics as potential predictors for therapeutic efficacy. It will also examine their efficacy and safety, the differences in their cardiovascular and renal benefits, aiming to convey clinical suggestions for everyday practice.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular; Chronic kidney disease; GLP-1 receptor agonists; Heart failure; SGLT-2 inhibitors

Year:  2019        PMID： 31821814     DOI： 10.1016/j.metabol.2019.154045

Source DB:  PubMed          Journal:  Metabolism        ISSN： 0026-0495            Impact factor:   8.694


  10 in total

1.  Glycaemic Control in Diabetes.

Authors:  D Müller-Wieland; J Brandts; M Verket; N Marx; K Schütt
Journal:  Handb Exp Pharmacol       Date:  2022

2.  The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique.

Authors:  Giuseppina Russo; Matteo Monami; Gianluca Perseghin; Angelo Avogaro; Pasquale Perrone Filardi; Michele Senni; Claudio Borghi; Aldo P Maggioni
Journal:  Diabetes Ther       Date:  2021-03-25       Impact factor: 2.945

Review 3.  GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

Authors:  Michael A Nauck; Daniel R Quast; Jakob Wefers; Juris J Meier
Journal:  Mol Metab       Date:  2020-10-14       Impact factor: 7.422

4.  When Inappropriate Use of Insulin is Dangerous: The Utility of C-Peptide Assay in the Era of Cardioprotective Antidiabetic Drugs.

Authors:  Sara Volpe; Cosimo Tortorella; Vincenzo Solfrizzi; Giuseppina Piazzolla
Journal:  Diabetes Metab Syndr Obes       Date:  2021-08-05       Impact factor: 3.168

Review 5.  Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies.

Authors:  Irene Caruso; Angelo Cignarelli; Gian Pio Sorice; Annalisa Natalicchio; Sebastio Perrini; Luigi Laviola; Francesco Giorgino
Journal:  Metabolites       Date:  2022-02-15

Review 6.  A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Khalid Al Rasadi; Mustafa Cesur; José Silva-Nunes; Anca Pantea Stoian; Manfredi Rizzo
Journal:  Metabolites       Date:  2022-01-24

Review 7.  Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update.

Authors:  Ioanna Koniari; Dimitrios Velissaris; Nicholas G Kounis; Eleni Koufou; Eleni Artopoulou; Cesare de Gregorio; Virginia Mplani; Themistoklis Paraskevas; Grigorios Tsigkas; Ming-Yow Hung; Panagiotis Plotas; Vaia Lambadiari; Ignatios Ikonomidis
Journal:  J Clin Med       Date:  2022-08-09       Impact factor: 4.964

8.  Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.

Authors:  Marta Baviera; Andreana Foresta; Pierluca Colacioppo; Giulia Macaluso; Maria Carla Roncaglioni; Mauro Tettamanti; Ida Fortino; Stefano Genovese; Irene Caruso; Francesco Giorgino
Journal:  Cardiovasc Diabetol       Date:  2022-08-24       Impact factor: 8.949

Review 9.  Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and results.

Authors:  Kevin M Pantalone; Kashif Munir; Clinton M Hasenour; Charles M Atisso; Oralee J Varnado; Juan M Maldonado; Manige Konig
Journal:  Diabetes Obes Metab       Date:  2020-09-06       Impact factor: 6.577

10.  Incretin-based therapies in 2021 - current status and perspectives for the future.

Authors:  Manfredi Rizzo; Michael A Nauck; Christos S Mantzoros
Journal:  Metabolism       Date:  2021-07-29       Impact factor: 8.694
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.